Cerevel Therapeutics Holdings, Inc. (CERE) Q1 2021 Results Earnings Conference Call May 17, 2021 8:00 AM ET
Company Participants
Matt Calistri - Vice President, Investor Relations
Tony Coles - Chairperson & Chief Executive Officer
Abraham Ceesay - President
Ray Sanchez - Chief Medical Officer
John Renger - Chief Scientific Officer
Kathy Yi - Chief Financial Officer
Conference Call Participants
Paul Matteis - Stifel
Michael Yee - Jefferies
Greg Suvannavejh - Goldman Sachs
Umer Raffat - Evercore
Operator
Good morning. Welcome to the Cerevel Therapeutics First Quarter 2021 Results - Financial Results Conference Call. At this time, all participants are in listen-only mode. Later, you will have a opportunity to ask questions during the Q&A portion of the call. Please note that this call maybe recorded.
I will now turn the call over to Matt Calistri, Vice President of Investor Relations.
Matt Calistri
Thank you. Good morning, everyone. We appreciate you joining us for our first quarter 2021 results call. On today’s call, you will be hearing from Dr. Tony Coles, our Chairperson and Chief Executive Officer; Dr. Ray Sanchez, our Chief Medical Officer; Dr. John Renger, our Chief Scientific Officer; and Kathy Yi, our Chief Financial Officer. We will also have brief introduction Ab Ceesay, our new President.
Please refer to our press release from this morning detailing our Q1 performance as well as our updated corporate presentation, both of which are available on our website. I would like to remind you that we will be making forward-looking statements that reflect our current views related to our financial performance, future events and industry and market conditions, as well as forward-looking statements, including the potential attributes and benefits of our product candidates, and the format and timing of Cerevel’s product development activities and clinical trials. We strongly encourage you to review the information that we filed with the
- Read more current CERE analysis and news
- View all earnings call transcripts